Clinical Trials Update: April 14, 2006
Breast Cancer Bipolar Disorders Crohn's Disease
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
This clinical trial will evaluate the effectiveness and safety of trastuzumab in combination with SU011248 or placebo in people with locally recurrent or metastatic breast cancer. Men and women at least 18 years old who have breast cancer with evidence of unresectable, locally recurrent or metastatic disease who have not had prior chemotherapy or trastuzumab in the advanced disease setting may qualify. The research sites are located in throughout the United States and Canada.
If you are diagnosed with bipolar disorder, are at least 18, and are looking to try an alternative medication, you may qualify to participate in this clinical research trial evaluating an investigational drug. Volunteers will receive clinical evaluations and examinations at no cost, and compensation for time and travel may be available. The research site is in Hoffman Estates, Ill.
This study will evaluate the effectiveness of Remicade (infliximab) and Imuran (azathioprine) to treat moderate-to-severe Crohn's disease. People at least 18 who have had Crohn's disease for at least six weeks duration confirmed by radiography or endoscopy may qualify. Candidates must have no history of treatment with azathioprine, infliximab, 6-mercaptopurine or 6-thioguanine, and cannot have had intra-abdominal surgery within six months. The research site is in Houston, Texas.
Copyright 2006 CenterWatch. All rights reserved.